UPLOAD Filing
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Date: May 7, 2025 · CIK: 0001335105 · Accession: 0000000000-25-004865
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Lixte Biotechnology Holdings, Inc. Draft Registration Statement on Form S-1 Submitted May 2, 2025 CIK No. 0001335105 Dear Bastiaan van der Baan:
May 7, 2025
Bastiaan van der Baan President and Chief Executive Officer Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, CA 91101
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: David Ficksman, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 7, 2025 Bastiaan van der Baan President and Chief Executive Officer Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, CA 91101 Re: Lixte Biotechnology Holdings, Inc. Draft Registration Statement on Form S-1 Submitted May 2, 2025 CIK No. 0001335105 Dear Bastiaan van der Baan: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Ficksman, Esq. </TEXT> </DOCUMENT>